Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant?

Transplantation

Volumn 85, Issue 8, 2008, Pages 1200-1204

  Gupta, Arun ^a   Iveson, Victoria ^a   Varagunam, Mira ^a   Bodger, Stephen ^a   Sinnott, Paul ^a   Thuraisingham, Raj C ^a,b  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Antibodies; Crossmatch; Kidney; Outcomes

Indexed keywords

ALLOANTIBODY; AZATHIOPRINE; CREATININE; CYCLOSPORIN A; PREDNISOLONE;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY TEST; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERACUTE GRAFT REJECTION; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS;

EID: 42549138892     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816b1c37     Document Type: Article

References (16)

1. Starzl TE, Lerner RA, Dixon FJ, et al. Shwartzman reaction after human renal homotransplantation. N Engl J Med 1968; 278: 642.
2. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
3. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: Lessons from pathology. Clin J Am Soc Nephrol 2006; 1: 415.
4. Nishikawa K, Terasaki PI. Annual trends and triple therapy - 1991-2000. In: Cecka JM, Terasaki PI, eds. Clinical transplants. 2001, p 247.
5. Worthington JE, Langton A, Liggett H, et al. A novel strategy for the detection and definition of HLA-specific antibodies in patients awaiting renal transplantation. Transpl Int 1998; 11(suppl 1): S372.
6. Duquesnoy RJ, Marrari M. Multilaboratory evaluation of serum analysis for HLA antibody and crossmatch reactivity by lymphocytotoxicity methods. Arch Pathol Lab Med 2003; 127: 149.
7. Grigsby SJ, D'souza JM, Banwart RP, et al. A comparison of CDC and Luminex for the detection of HLA antibody. Hum Immunol 2005; 66(8 suppl): 88.
8. Zachary AA, Ratner LE, Graziani JA, et al. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. Hum Immunol 2001; 62: 236.
9. Kao KJ, Scornik JC, Small SJ. Enzyme-linked immunoassay for anti-HLA antibodies - An alternative to panel studies by lymphocytotoxicity. Transplantation 1993; 55: 192.
10. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
11. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A paired donor kidney analysis. Transplantation 2002; 74: 1377.
12. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 2006; 6: 2307.
13. Taylor CJ, Smith SI, Morgan CH, et al. Selective omission of the donor cross-match before renal transplantation: Efficacy, safety and effects on cold storage time. Transplantation 2000; 69: 719.
14. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864.
15. Pelletier RP, Hennessy PK, Adams PW, et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2002; 2: 134.
16. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2-year prospective trial. Transplantation 2005; 80: 1194.